Overview of Virus Spike Preparations Studied
| Virus Name | Abbr. | Family | Size (nm) | Genome | Envelope | Sources |
|---|---|---|---|---|---|---|
| Murine minute virus | MMV | Parvoviridae | 18–26 | ssDNA | No | a, b, d, e |
| Murine leukemia virus | MuLV | Retroviridae | 80–110 | ssRNA | Yes | a, b, d |
| Poliovirus | Pol | Picornaviridae | 22–30 | ssRNA | No | a1, a2 |
| Porcine parvovirus | PPV | Parvoviridae | 18–26 | ssDNA | No | a, b, c, d, e |
| Pseudorabies virus | PRV | Herpesviridae | 120–200 | dsDNA | Yes | a, d |
| Reovirus type 3 | Reo-3 | Reoviridae | 60–80 | dsRNA | No | d1, d2 |
Viruses chosen for study are commonly-used model viruses in the biotech industry (4) and range by physicochemical features such as size (diameter), genome type, and presence or absence of envelope. A total of 18 preparations were characterized in this study and originated from one of up to five sources. Abbr., abbreviation of virus name commonly used in the field.